Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

View Category
Mitral valve

TCT 2025 | Transcatheter Mitral Valve Replacement with SAPIEN M3: ENCIRCLE 1-Year Outcomes

Transcatheter mitral valve replacement (TMVR) is an emerging option for patients with symptomatic mitral regurgitation (MR) who...
Dr. Juan Manuel Pérez -
Learn More
Structural Heart Disease

TCT 2025 | PARTNER 3 Trial 7-Year Outcomes: TAVR vs SAVR in Low-Risk Patients

The randomized PARTNER 3, which initially showed TAVR superiority when using the SAPIEN 3 valve over SAVR...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

Impact of Amyloidosis on Outcomes After TAVI

Cardiac amyloidosis (CA) is a systemic and progressive disease characterized by the accumulation of misfolded proteins in...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

What Factors Predict Permanent Pacemaker Implantation after TAVR? CONDUCT-TAVI Outcomes

Permanent pacemaker implantation (PPM) for high grade atrioventricular block (AVB) continues to be one of the most...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

When Is the Optimal Time for Aortic Valve Replacement? Impact of Acute Valvular Syndrome on Outcomes and Costs

According to the clinical presentation before aortic valve replacement (AVR), a new classification has recently been proposed:...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

In Hospital Complications after Transcatheter Aortic Valve Replacement in Bicuspid vs. Tricuspid Aortic Valves: A Retrospective Cohort Study

Courtesy of Dr. Juan Manuel Pérez.  Bicuspid aortic valves (BAV), present in 0,5 to 2% of the population,...
Dr. Juan Manuel Pérez -
Learn More
Structural heart disease

Is the Acceleration Time/Ejection Time Ratio Superior to the Mean Gradient in Predicting Clinical Outcomes After TAVR?

Courtesy of Dr. Juan Manuel Pérez. Traditionally, the mean gradient (MG) has been used to assess post-TAVR outcomes....
Dr. Juan Manuel Pérez -
Learn More
Coronary disease

Coronary Events after TAVI according to the FRANCE Registry

Between 30% and 70% of patients undergoing transcatheter aortic valve replacement (TAVR) present with coronary artery disease...
Dr. Andrés Rodríguez -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy